

## Iclusig™ (ponatinib) (Oral)

Document Number: IC-0164

Last Review Date: 07/03/2018

Date of Origin: 02/07/2013

Dates Reviewed: 01/2014, 08/2014, 07/2015, 07/2016, 08/2017, 07/2018

### I. Length of Authorization

Coverage will be provided for six months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- Iclusig 15 mg tablet: 2 tablets per day
- Iclusig 30 mg tablet: 1 tablet per day
- Iclusig 45 mg tablet: 1 tablet per day

#### B. Max Units (per dose and over time) [Medical Benefit]:

- 45 mg daily

### III. Initial Approval Criteria

Coverage is provided in the following conditions:

#### Acute lymphoblastic leukemia (ALL) †

- Patient's disease is Philadelphia chromosome-positive (Ph+); **AND**
- Patient is aged at least 15 years old; **AND**
  - Disease is T315I mutation positive †; **OR**
  - Patient has failed multiple tyrosine kinase inhibitors (TKI) †; **OR**
  - Used as single agent or in combination with an induction regimen not previously given for relapsed/refractory disease; **OR**
  - Used as part of induction/consolidation therapy in combination with HyperCVAD (hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine); **OR**
  - Used as maintenance therapy; **AND**
    - In combination with vincristine and prednisone; **OR**
    - Post stem-cell transplant

### Chronic myelogenous leukemia (CML) †

- Patient is at least 18 years old; **AND**
- *BCR-ABL1* positive laboratory test result; **AND**

#### Chronic or accelerated or blast phase disease †

- Patient's disease is T315I mutation positive †; **OR**
- Patient is resistant, or intolerant, or had an inadequate response to prior tyrosine kinase inhibitor (TKI) therapies, consisting of a 3 month trial or longer, with any of the following: omacetaxine, imatinib, dasatinib, bosutinib, nilotinib, etc. †

#### Primary Treatment ‡

- Used as single agent for accelerated phase disease; **OR**
- Used as single agent for myeloid blast phase disease; **OR**
- In combination with steroids for lymphoid blast phase disease; **OR**
- In combination with induction chemotherapy for lymphoid or myeloid blast phase disease

#### Post-allogeneic hematopoietic stem cell transplant (HCT) ‡

- Used in patients with a complete cytogenetic response (CCyR) for accelerated or blast phase disease; **OR**
- Used in patients with molecular relapse (*BCR-ABL1* transcript positive) following CCyR; **OR**
- Used as follow-up therapy in patients with relapse or those who are not in CCyR

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s)

## IV. Renewal Criteria

Coverage can be renewed based upon the following criteria:

- Patient continues to meet criteria in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: thromboembolism and vascular occlusion; hepatotoxicity; ocular toxicity; hypertensive crisis; serious congestive heart failure; pancreatitis; serious or severe hemorrhage; fluid retention (peripheral edema, pleural effusion, and pericardial effusion); cardiac arrhythmia; Grade 3 or 4 myelosuppression; tumor lysis syndrome; gastrointestinal perforation; poor wound healing; **AND**
- Patient has been adherent to therapy; **AND**

#### Acute lymphoblastic leukemia (ALL) only:

- Treatment response or stabilization of disease as indicated by CBC, bone marrow cytogenic analysis, QPCR, or FISH

#### Chronic Myelogenous Leukemia (CML) only:

- Treatment response as indicated by one of the following *BCR-ABL1* (IS) transcript levels:

- ≤ 10% at 3 months; **OR**
- ≤ 10% at 6 months; **OR**
- < 1% at 12 months; **OR**
- < 0.1% beyond 12 months

NOTE: cytogenetic assessment of response may be used if quantitative RT-PCR (QPCR) using International Scale (IS) for *BCR-ABL1* is not available

## V. Dosage/Administration

Indication	Dose
All Indications	45 mg administered orally once daily.

## VI. Billing Code/Availability Information

### Jcode:

- C9399: Unclassified drugs or biologicals, (Hospital Outpatient Use ONLY)
- J8999: Prescription drug, oral, chemotherapeutic, NOS

### NDC:

- Iclusig 15 mg tablet: 63020-0535-xx
- Iclusig 30 mg tablet: 63020-0533-xx
- Iclusig 45 mg tablet: 63020-0534-xx

## VII. References

1. Iclusig [package insert]. Cambridge, MA; Takeda Pharmaceuticals Company Limited; December 2017. Accessed June 2018.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia. 1.2018. National Comprehensive Cancer Network, 2017. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2018.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Chronic Myelogenous Leukemia 4.2018. National Comprehensive Cancer Network, 2017. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2018.
4. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for ponatinib. 2018 National Comprehensive Cancer Network. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2018.

### Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C91.00	Acute lymphoblastic leukemia, not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse

### Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC